share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1:证券上市注册声明
美股SEC公告 ·  2024/11/22 13:41

Moomoo AI 已提取核心信息

Cardio Diagnostics Holdings, Inc., formed through a merger in October 2022, specializes in AI-driven DNA biomarker tests for cardiovascular diseases. Despite innovative products like Epi+Gen CHD™ and PrecisionCHD™, the company reported minimal revenue and a net loss of $8.4 million in 2023. As of September 30, 2024, it holds $3 million in cash.The company trades on Nasdaq under CDIO but received a notice of non-compliance with the $1 minimum bid price. Leadership includes CEO Meeshanthini Dogan and CFO Elisa Luqman. Cardio Diagnostics raised funds through various means, including a $5 million convertible debenture in March 2023 and a $1 million private placement in February 2024.Key risks involve limited operating history and the need for additional capital. The company focuses on commercializing its tests through telemedicine and healthcare providers.
Cardio Diagnostics Holdings, Inc., formed through a merger in October 2022, specializes in AI-driven DNA biomarker tests for cardiovascular diseases. Despite innovative products like Epi+Gen CHD™ and PrecisionCHD™, the company reported minimal revenue and a net loss of $8.4 million in 2023. As of September 30, 2024, it holds $3 million in cash.The company trades on Nasdaq under CDIO but received a notice of non-compliance with the $1 minimum bid price. Leadership includes CEO Meeshanthini Dogan and CFO Elisa Luqman. Cardio Diagnostics raised funds through various means, including a $5 million convertible debenture in March 2023 and a $1 million private placement in February 2024.Key risks involve limited operating history and the need for additional capital. The company focuses on commercializing its tests through telemedicine and healthcare providers.
Cardio Diagnostics Holdings, Inc. 于2022年10月通过合并成立,专门从事人工智能驱动的心血管疾病DNA生物标志物测试。尽管有Epi+Gen CHD™ 和PrecisionCHD™ 等创新产品,但该公司报告称,2023年收入微乎其微,净亏损840万美元。截至2024年9月30日,它持有300万美元的现金。该公司根据CDIO在纳斯达克交易,但收到了不遵守1美元最低出价的通知。领导层包括首席执行官 Meeshanthini Dogan 和首席财务官 Elisa Luqman。Cardio Diagnostics通过各种方式筹集了资金,包括2023年3月的500万美元可转换债券和2024年2月的100万美元私募债券。主要风险涉及有限的运营历史和对额外资本的需求。该公司专注于通过远程医疗和医疗保健提供商将其测试商业化。
Cardio Diagnostics Holdings, Inc. 于2022年10月通过合并成立,专门从事人工智能驱动的心血管疾病DNA生物标志物测试。尽管有Epi+Gen CHD™ 和PrecisionCHD™ 等创新产品,但该公司报告称,2023年收入微乎其微,净亏损840万美元。截至2024年9月30日,它持有300万美元的现金。该公司根据CDIO在纳斯达克交易,但收到了不遵守1美元最低出价的通知。领导层包括首席执行官 Meeshanthini Dogan 和首席财务官 Elisa Luqman。Cardio Diagnostics通过各种方式筹集了资金,包括2023年3月的500万美元可转换债券和2024年2月的100万美元私募债券。主要风险涉及有限的运营历史和对额外资本的需求。该公司专注于通过远程医疗和医疗保健提供商将其测试商业化。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息